Biocon Limited — Updates, 03-07-2025: Press Release

Biocon Biologics has announced a board meeting to review the financial results for the quarter and half-year. The European Commission has approved its Denosumab biosimilars, Vevzuo® and Evfraxy®, expanding its footprint in bone health across the EU. These biosimilars target osteoporosis, bone complications in cancer, and giant cell tumors, addressing a large patient population. This regulatory milestone strengthens Biocon’s global biosimilars portfolio, supporting revenue growth potential in advanced markets like Europe.